HRP20010468B1 - Azabicycloalkanes as ccr5 modulators - Google Patents

Azabicycloalkanes as ccr5 modulators

Info

Publication number
HRP20010468B1
HRP20010468B1 HRP20010468AA HRP20010468A HRP20010468B1 HR P20010468 B1 HRP20010468 B1 HR P20010468B1 HR P20010468A A HRP20010468A A HR P20010468AA HR P20010468 A HRP20010468 A HR P20010468A HR P20010468 B1 HRP20010468 B1 HR P20010468B1
Authority
HR
Croatia
Prior art keywords
alkyl
optionally substituted
substituents
alkoxy
phenyl
Prior art date
Application number
HRP20010468AA
Other languages
English (en)
Croatian (hr)
Inventor
Robert Armour Duncan
Anthony Price David
Luiza Christa Stammen Blanda
Wood Anthony
Perros Manoussos
Paul Edwards Martin
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9828420.1A external-priority patent/GB9828420D0/en
Priority claimed from GBGB9921375.3A external-priority patent/GB9921375D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HRP20010468A2 publication Critical patent/HRP20010468A2/hr
Publication of HRP20010468B1 publication Critical patent/HRP20010468B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HRP20010468AA 1998-12-23 2001-06-19 Azabicycloalkanes as ccr5 modulators HRP20010468B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9828420.1A GB9828420D0 (en) 1998-12-23 1998-12-23 CCR5 antagonists useful as anti-hiv agents
GBGB9921375.3A GB9921375D0 (en) 1999-09-10 1999-09-10 CCR5 Modulators
PCT/IB1999/002048 WO2000038680A1 (en) 1998-12-23 1999-12-23 Azabicycloalkanes as ccr5 modulators

Publications (2)

Publication Number Publication Date
HRP20010468A2 HRP20010468A2 (en) 2003-02-28
HRP20010468B1 true HRP20010468B1 (en) 2012-06-30

Family

ID=26314899

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20010468AA HRP20010468B1 (en) 1998-12-23 2001-06-19 Azabicycloalkanes as ccr5 modulators
HRP20120132AA HRP20120132B1 (hr) 1998-12-23 2012-02-09 Azabicikloalkani u svojstvu modulatora ccr5

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20120132AA HRP20120132B1 (hr) 1998-12-23 2012-02-09 Azabicikloalkani u svojstvu modulatora ccr5

Country Status (48)

Country Link
US (1) US6586430B1 (uk)
EP (1) EP1140085B1 (uk)
JP (1) JP3602795B2 (uk)
KR (1) KR100425612B1 (uk)
CN (1) CN1331591A (uk)
AP (1) AP1697A (uk)
AR (1) AR024233A1 (uk)
AT (1) ATE505190T1 (uk)
AU (1) AU763644B2 (uk)
BG (1) BG65448B1 (uk)
BR (1) BRPI9917007B8 (uk)
CA (1) CA2350073C (uk)
CO (1) CO5300387A1 (uk)
CR (2) CR9879A (uk)
CU (1) CU23344A3 (uk)
CY (1) CY1111504T1 (uk)
CZ (1) CZ300926B6 (uk)
DE (1) DE69943352D1 (uk)
DK (1) DK1140085T3 (uk)
DZ (2) DZ2979A1 (uk)
EA (1) EA004988B1 (uk)
EE (1) EE05170B1 (uk)
EG (1) EG24400A (uk)
GC (1) GC0000117A (uk)
GE (1) GEP20033131B (uk)
HK (1) HK1039902A1 (uk)
HR (2) HRP20010468B1 (uk)
HU (1) HU228754B1 (uk)
ID (1) ID28965A (uk)
IL (2) IL143512A0 (uk)
IS (1) IS5944A (uk)
MA (1) MA26714A1 (uk)
ME (1) ME00513B (uk)
NO (1) NO330677B1 (uk)
NZ (1) NZ511794A (uk)
OA (1) OA11735A (uk)
PA (1) PA8487201A1 (uk)
PE (1) PE20001420A1 (uk)
PL (1) PL201875B1 (uk)
PT (1) PT1140085E (uk)
RS (1) RS51701B (uk)
SI (1) SI1140085T1 (uk)
SK (1) SK287020B6 (uk)
TN (1) TNSN99252A1 (uk)
TR (1) TR200101793T2 (uk)
TW (1) TW577888B (uk)
UA (1) UA72750C2 (uk)
WO (1) WO2000038680A1 (uk)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
US7217714B1 (en) * 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
US6399619B1 (en) 1999-04-06 2002-06-04 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
EP1118858A3 (en) * 2000-01-12 2003-07-09 Pfizer Limited Assay method
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
NZ521477A (en) 2000-05-26 2004-07-30 Pfizer Tropane derivatives useful in therapy
US6667314B2 (en) * 2000-05-26 2003-12-23 Pfizer, Inc. Tropane derivatives useful in therapy
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
US6511994B2 (en) 2000-10-11 2003-01-28 Merck & Co., Inc. Modulators of CCR5 chemokine receptor activity
US6531484B2 (en) 2000-10-11 2003-03-11 Merck & Co., Inc. Pyrrolidine modulators of CCR5 chemokine receptor activity
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
EP1354587A1 (en) * 2000-12-22 2003-10-22 Takeda Chemical Industries, Ltd. Medicinal compositions for oral use
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
SE0103818D0 (sv) * 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
TW200305395A (en) * 2002-03-15 2003-11-01 Novartis Ag Organic compounds
DK1492789T3 (da) * 2002-04-08 2006-09-11 Pfizer Tropanderivater som CCR5-modulatorer
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
BR0309982A (pt) * 2002-05-23 2005-03-22 Pfizer Método para identificação de um ligando, pelo qual o tempo de residência no receptor é medido
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
US7202259B2 (en) 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
JP4666256B2 (ja) * 2002-12-10 2011-04-06 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
AU2003300902A1 (en) * 2002-12-13 2004-07-09 Smithkline Beecham Corporation Piperidine derivatives as CCR5 antagonists
AU2003296993A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Cyclopropyl compounds as ccr5 antagonists
CA2517888C (en) 2003-03-14 2012-05-01 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
WO2004092169A1 (ja) 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
ATE361911T1 (de) * 2003-07-31 2007-06-15 Astrazeneca Ab Piperidinderivate als ccr5-rezeptormodulatoren
US7220772B2 (en) 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
CA2579609A1 (en) 2003-09-10 2005-03-17 Virochem Pharma Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
AP2174A (en) * 2003-10-03 2010-11-20 Pfizer Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflamation.
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
EP1709029A2 (en) * 2004-01-30 2006-10-11 Euro-Celtique S.A. Methods for making 4-tetrazolyl-4-phenylpiperidine compounds
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
WO2005100322A1 (en) * 2004-04-14 2005-10-27 Pfizer Limited Sulphur-linked imidazole compounds for the treament of hiv
TW200610761A (en) * 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
CN101001860A (zh) 2004-06-09 2007-07-18 霍夫曼-拉罗奇有限公司 杂环抗病毒化合物
RU2409565C2 (ru) 2004-09-13 2011-01-20 Оно Фармасьютикал Ко., Лтд. Азотистые гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента
JP2008534654A (ja) * 2005-04-08 2008-08-28 ノイロサーチ アクティーゼルスカブ （＋）−及び（−）−８−アルキル−３−（トリフルオロアルキルスルホニルオキシ）−８−アザビシクロ（３．２．１）オクト−２−エン
MX2007012477A (es) 2005-04-14 2007-11-08 Hoffmann La Roche Derivados de aminopirazol, su fabricacion y uso como agentes farmaceuticos.
WO2006129679A1 (ja) 2005-05-31 2006-12-07 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
ES2277745B1 (es) * 2005-06-14 2008-06-01 Laboratorios Almirall S.A. Derivados n-amida de 8-azabiciclo /3.2.1/oct-3-ilo como antagonistas de ccr1.
ES2427989T3 (es) 2005-10-28 2013-11-05 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
ES2407115T3 (es) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
JPWO2007105637A1 (ja) 2006-03-10 2009-07-30 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
US20080015835A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for treating disease
US20090082344A1 (en) * 2006-07-13 2009-03-26 Searete Llc Methods and systems for treating disease
US20080015787A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for treating disease
US20080015833A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for molecular inhibition of protein misfolding
US20090325992A1 (en) 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
CA2673566A1 (en) * 2006-12-19 2008-06-26 Auspex Pharmaceuticals, Inc. Preparation and utility of ccr5 inhibitors
KR20120102172A (ko) 2007-08-31 2012-09-17 시오노기세이야쿠가부시키가이샤 치환-퀴녹살린-형 피페리딘 화합물 및 그의 용도
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
WO2011011652A1 (en) 2009-07-24 2011-01-27 Glaxosmithkline Llc Therapeutic compounds
PE20130529A1 (es) 2010-04-02 2013-05-14 Phivco 1 Llc Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico
WO2012122499A2 (en) 2011-03-09 2012-09-13 Pestell Richard G Prostate cancer cell lines, gene signatures and uses thereof
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
CA2873743C (en) * 2012-05-14 2022-12-06 Prostagene, Llc Using modulators of ccr5 for treating cancer
WO2014102594A2 (en) * 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
EP3826659B1 (en) * 2018-07-10 2024-06-19 Rush University Medical Center Immunomodulator for use in the treatment of a bacterial infection
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0630887A1 (en) * 1993-05-24 1994-12-28 Zeneca Limited 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists
WO1996024582A1 (en) * 1995-02-10 1996-08-15 Zeneca Limited 5-(4-subst.-piperidinyl-1)-3-aryl-pentanoic acid derivatives as tachykinin receptor antagonist
WO1997019060A1 (en) * 1995-11-17 1997-05-29 Zeneca Limited 3-(4-subst.-piperidinyl-1)-1-(3,4-dichlorophenyl)propyl carbamates and ureas and derivatives as novel neurokinin antagonists
WO1997024325A1 (en) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
WO1998002151A2 (en) * 1996-07-12 1998-01-22 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
WO1998025604A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998025605A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998025617A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
WO1999004794A1 (en) * 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
EP0903349A2 (en) * 1997-08-18 1999-03-24 F. Hoffmann-La Roche Ag CCR-3 receptor antagonists
WO1999017773A1 (en) * 1997-10-07 1999-04-15 Smithkline Beecham Corporation Compounds and methods
WO1999037619A1 (en) * 1998-01-21 1999-07-29 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO1999037617A1 (en) * 1998-01-21 1999-07-29 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125900D0 (en) 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
PH30413A (en) 1992-03-26 1997-05-09 Boehringer Ingelheim Italia Crystalline forms of endo-2,3-dihydro-n-(8-methyl)-8-azabicyclo-(3,2,1)oct-3-yl)-2-oxo-1h-benzimidazole-1-carboxamides
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
SK1296A3 (en) * 1995-01-04 1996-08-07 Bayer Ag Acyled pseudopeptides with trifluoromethyl-substituted 2-azabicyklooctane, manufacturing process thereof and medicaments containing these substances
EA002270B1 (ru) * 1996-03-29 2002-02-28 Пфайзер Инк. Производные 6-фенилпиридил-2-амина
WO1998004554A1 (fr) * 1996-07-29 1998-02-05 Banyu Pharmaceutical Co., Ltd. Antagonistes de recepteurs de chemokines
EP1003743A4 (en) 1997-01-21 2001-04-11 Merck & Co Inc 3,3-DISBSTITUED PIPERIDINE LIKE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
EP1009405A4 (en) 1997-08-28 2001-05-09 Merck & Co Inc MODULATORS OF PYRROLIDINE AND PIPERIDINE OF CHEMOKINE RECEPTOR ACTIVITY

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0630887A1 (en) * 1993-05-24 1994-12-28 Zeneca Limited 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists
WO1996024582A1 (en) * 1995-02-10 1996-08-15 Zeneca Limited 5-(4-subst.-piperidinyl-1)-3-aryl-pentanoic acid derivatives as tachykinin receptor antagonist
WO1997019060A1 (en) * 1995-11-17 1997-05-29 Zeneca Limited 3-(4-subst.-piperidinyl-1)-1-(3,4-dichlorophenyl)propyl carbamates and ureas and derivatives as novel neurokinin antagonists
WO1997024325A1 (en) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
WO1998002151A2 (en) * 1996-07-12 1998-01-22 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
WO1998025604A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998025605A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998025617A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
WO1999004794A1 (en) * 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
EP0903349A2 (en) * 1997-08-18 1999-03-24 F. Hoffmann-La Roche Ag CCR-3 receptor antagonists
WO1999017773A1 (en) * 1997-10-07 1999-04-15 Smithkline Beecham Corporation Compounds and methods
WO1999037619A1 (en) * 1998-01-21 1999-07-29 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO1999037617A1 (en) * 1998-01-21 1999-07-29 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor

Also Published As

Publication number Publication date
CU23344A3 (es) 2009-02-20
HRP20120132B1 (hr) 2018-01-26
TR200101793T2 (tr) 2001-12-21
PT1140085E (pt) 2011-06-16
JP3602795B2 (ja) 2004-12-15
UA72750C2 (en) 2005-04-15
HUP0104795A2 (hu) 2002-04-29
BRPI9917007B8 (pt) 2021-05-25
CN1331591A (zh) 2002-01-16
DZ2979A1 (fr) 2005-01-30
CA2350073C (en) 2007-04-17
BG105721A (en) 2002-02-28
CR9879A (es) 2008-06-20
PE20001420A1 (es) 2000-12-18
CR6392A (es) 2006-08-09
NO330677B1 (no) 2011-06-06
EE200100345A (et) 2002-12-16
EG24400A (en) 2009-04-29
TW577888B (en) 2004-03-01
HRP20010468A2 (en) 2003-02-28
OA11735A (en) 2005-05-12
CA2350073A1 (en) 2000-07-06
KR20010089701A (ko) 2001-10-08
US6586430B1 (en) 2003-07-01
BRPI9917007B1 (pt) 2016-07-26
AP2001002186A0 (en) 2001-06-30
JP2002533393A (ja) 2002-10-08
DZ3326A1 (fr) 2005-05-29
EE05170B1 (et) 2009-06-15
BG65448B1 (bg) 2008-08-29
DK1140085T3 (da) 2011-06-27
BR9917007A (pt) 2001-10-30
NO20013183L (no) 2001-08-08
HU228754B1 (en) 2013-05-28
HRP20120132A2 (hr) 2012-03-31
PA8487201A1 (es) 2002-02-21
SK8752001A3 (en) 2003-02-04
CY1111504T1 (el) 2015-08-05
CZ20012298A3 (cs) 2002-09-11
TNSN99252A1 (fr) 2005-11-10
ATE505190T1 (de) 2011-04-15
IL143512A0 (en) 2002-04-21
WO2000038680A1 (en) 2000-07-06
EP1140085B1 (en) 2011-04-13
HK1039902A1 (zh) 2002-05-17
YU38801A (sh) 2005-06-10
MA26714A1 (fr) 2004-12-20
ME00513B (me) 2011-10-10
HRP20120132A8 (hr) 2017-11-03
GC0000117A (en) 2005-06-29
AR024233A1 (es) 2002-09-25
EA004988B1 (ru) 2004-10-28
SK287020B6 (sk) 2009-09-07
NO20013183D0 (no) 2001-06-25
EP1140085A1 (en) 2001-10-10
KR100425612B1 (ko) 2004-04-01
IS5944A (is) 2001-05-15
GEP20033131B (en) 2003-12-25
CZ300926B6 (cs) 2009-09-09
AU763644B2 (en) 2003-07-31
AU1675100A (en) 2000-07-31
CO5300387A1 (es) 2003-07-31
SI1140085T1 (sl) 2011-08-31
ID28965A (id) 2001-07-19
AP1697A (en) 2006-12-22
PL349495A1 (en) 2002-07-29
DE69943352D1 (de) 2011-05-26
EA200100589A1 (ru) 2002-02-28
PL201875B1 (pl) 2009-05-29
RS51701B (sr) 2011-10-31
IL143512A (en) 2013-06-27
NZ511794A (en) 2003-10-31
HUP0104795A3 (en) 2002-05-28

Similar Documents

Publication Publication Date Title
HRP20010468B1 (en) Azabicycloalkanes as ccr5 modulators
RS52313B (en) MYTHOSIS PROGRESS INHIBITION UNITS
AR049418A1 (es) Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
ID29452A (id) 4-okso-1,4-dihidro-3-quinolinkarboksamida sebagai agen-agen antivirus
WO2000047580A3 (en) Phenyl urea and phenyl thiourea derivatives
CA2315050A1 (en) Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof
EA200000731A1 (ru) Альфа-аминоамидные производные, полезные в качестве анальгетических агентов
ES2422383T3 (es) Activadores de urea glucoquinasa
TW200606137A (en) Urea derivatives
CA2057913A1 (en) N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
EP1325921A3 (en) Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators
NO20054791L (no) Forbindelser for behandling av stoffskiftesykdommer
EA200300333A1 (ru) Новые тиадиазолы и оксадиазолы и их применение в качестве ингибиторов фосфодиэстеразы-7
TW200714674A (en) Near-infrared absorbing material and use thereof
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы
SE8305160L (sv) Antibakteriella emnen
DK1468692T3 (da) Anvendelse af 2,6-di-alkyl-4-silyl-phenoler til behandling af xantom
AR046310A1 (es) Compuestos nucleosidicos para el tratamiento de enfermedades virales. composiciones farmaceuticas.
HRP20060023A2 (en) Use of bicyclo[2.2.1]heptane derivatives for the preparation of neuroprotective pharmaceutical compositions
CO5690581A2 (es) Derivados de cicloalquilo 1,3-sustituidos que tienen grupos acidicos principalmente grupos heterociclicos; procedimientos para su preparacion y su uso como medicamentos
AR018632A1 (es) Compuestos derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene, proceso para su preparacion.
TW200505446A (en) Inhibitor of cox
KR920000744A (ko) 2-아미노알킬-5-아릴 알킬-1,3- 디옥산 유도체의 제조법 및 치료학적 용도
RU2008104422A (ru) Активатор рецептора дельта, активируемого пролифератором
RU2007135745A (ru) АКТИВАТОР δ- РЕЦЕПТОРА, АКТИВИРУЕМОГО ПРОЛИФЕРАТОРОМ ПЕРОКСИСОМЫ

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20181204

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20191223